11-脱氢血栓烷 b2 | 67910-12-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 11-脱氢血栓烷 b2
• 中文别名: 11-脱氢血栓烷b2；11-脱氢凝血烷B2
• 英文名称: 11-dehydrothromboxane B2
• 英文别名: 11-Dehydro-thromboxane B2；(Z)-7-[(2R,3S,4S)-4-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-6-oxooxan-3-yl]hept-5-enoic acid
• CAS: 67910-12-7
• 化学式: C₂₀H₃₂O₆
• 分子量: 368.47
• InChiKey: KJYIVXDPWBUJBQ-UHHGALCXSA-N

物化性质

• 沸点：
  588.5±50.0 °C(Predicted)
• 密度：
  1.167±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于乙腈（少许）、氯仿（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  26
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  11-脱氢血栓烷 b2 生成 凝血烷
  参考文献：
  名称：

  YARVING, I.;VARVAS, K.;VAXEMETS, A.;SAMEL, N.;LILLE, YU., 9. SOV.-IND. SIMP. PO XIMII PRIROD. SOED., RIGA, 15-18 MAYA, 1989, RIGA,(+

  摘要：

  DOI：
• 作为产物：
  描述：

  前列腺素 D2 以70%的产率得到
  参考文献：
  名称：

  YARVING, I.;VARVAS, K.;VAXEMETS, A.;SAMEL, N.;LILLE, YU., 9. SOV.-IND. SIMP. PO XIMII PRIROD. SOED., RIGA, 15-18 MAYA, 1989, RIGA,(+

  摘要：

  DOI：

文献信息

• Transformation of Prostaglandin D₂to 11‐Dehydro Thromboxane B₂by Baeyer‐Villiger Oxidation
  作者：Fumie Nakashima、Claus Schneider

  DOI：10.1002/lipd.12206

  日期：2020.1

  Prostaglandin D2 is one of five chief prostanoids formed in the cyclooxygenase pathway of arachidonic acid oxidation. Except for a single oxygen atom, PGD2 is structurally identical to 11‐dehydro thromboxane B2 (11d‐TxB2), a urinary metabolite of the pro‐aggregatory platelet activator, thromboxane A2. The close structural relationship suggested that one might be transformed to the other. Accordingly

  前列腺素D 2是在花生四烯酸氧化的环氧合酶途径中形成的五个主要前列腺素之一。除单个氧原子外，PGD 2与11-脱氢血栓烷B 2（11d-TxB 2）在结构上相同，后者是促凝血小板活化剂血栓烷A 2的尿代谢产物。紧密的结构关系表明一个可能会转化为另一个。因此，我们测试了PGD 2的环戊酮是否可以在Baeyer-Villiger氧化反应中扩展为11d-TxB 2的δ-内酯。用两种标准氧化剂对PGD 2进行氧化显示11d-TxB 2仅用H 2 O 2形成，而不用过乙酸形成。H 2 O 2介导的氧化反应的副产物是氢过氧化物衍生物和PGD 2的异构体。PGD 2到11d-TxB 2的化学氧化可能是等效酶转化的模型，表明PGD 2和血栓烷A 2的代谢可能存在联系。
• Polarity-Tuning Derivatization-LC-MS Approach for Probing Global Carboxyl-Containing Metabolites in Colorectal Cancer
  作者：Xiqing Bian、Na Li、Binbin Tan、Baoqing Sun、Ming-Quan Guo、Guoxin Huang、Li Fu、W. L. Wendy Hsiao、Liang Liu、Jian-Lin Wu

  DOI：10.1021/acs.analchem.8b01873

  日期：2018.10.2

  Carboxyl-containing metabolites (CCMs) widely exist in living systems and are the essential components for life. Global characteristics of CCMs in biological samples are critical for the understanding of physiological processes and the discovery for the onset of relevant diseases. However, their determination represents a challenge due to enormous polarity differences, structural diversity, high structural similarity, and poor ionization efficiency in mass spectrometry. Herein, 5-(diisopropylamino)amylamine (DIAAA) derivatization coupled with liquid chromatography–mass spectrometry (LC-MS) was developed for mapping the CCMs. With this methodology, the sensitivity was significantly enhanced. More importantly, the hydrophobicity of polar CCMs, amino acids, TCA cycle intermediates, and short-chain fatty acids and the hydrophilicity of low-polar CCMs, long-chain fatty acids, and bile acids were significantly increased, resulting in a remarkable separation efficiency for which 68 CCMs can be simultaneously determined. Furthermore, the polarity-tuning effect was confirmed to be induced by the different impacts of aliphatic chains and nitrogen atom in DIAAA, the latter existing as a cation in the acidic mobile phase, using different derivatization reagents. Finally, this derivatization method was utilized to hunt for the potential biomarkers in colorectal cancer (CRC) patients and 52 CCMs, related with several key metabolic pathways, including amino acids metabolism, TCA cycle, fatty acid metabolism, pyruvate metabolism, and gut flora metabolism were identified. This innovative polarity-tuning derivatization-LC-MS approach was proved to be a valuable tool for probing global metabolome with high separation efficiency and sensitivity in various biological samples.

  含羧基代谢物（CCMs）广泛存在于生物系统中，是生命的基本组成部分。CCMs在生物样本中的全球特征对于理解生理过程和发现相关疾病的发生具有重要意义。然而，由于极性差异巨大、结构多样性、高结构相似性和在质谱中的离子化效率较低，它们的测定面临挑战。在此，我们开发了5-(二异丙基氨基)戊胺（DIAAA）衍生化结合液相色谱-质谱（LC-MS）的方法以绘制CCMs的分布。通过这种方法，灵敏度显著提高。更重要的是，极性CCMs、氨基酸、TCA循环中间体和短链脂肪酸的疏水性显著增强，而低极性CCMs、长链脂肪酸和胆汁酸的亲水性也显著增加，从而实现了卓越的分离效率，使得68种CCMs可以同时测定。此外，极性调节效应被证实是由于DIAAA中脂肪链和氮原子的不同影响所引起的，后者在酸性流动相中以阳离子的形式存在，使用不同的衍生化试剂。最后，该衍生化方法被用于寻找结直肠癌（CRC）患者的潜在生物标志物，识别出52种与多条关键代谢通路（包括氨基酸代谢、TCA循环、脂肪酸代谢、丙酮酸代谢和肠道菌群代谢）相关的CCMs。这种创新的极性调节衍生化-LC-MS方法被证明是探测各种生物样本全球代谢组的高分离效率和灵敏度的有价值工具。
• Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
  申请人：Bennani L. Youssef

  公开号：US20060100425A1

  公开（公告）日：2006-05-11

  The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D 2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.

  本发明涉及吲哚乙酸化合物，其作为CRTH2受体的拮抗剂。本发明还涉及使用这些化合物来抑制前列腺素D2及其代谢物或某些血栓素代谢物与CRTH2受体的结合，并治疗对此类抑制有响应的疾病。
• INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF
  申请人：Bennani Youssef L.

  公开号：US20100016389A1

  公开（公告）日：2010-01-21

  The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D 2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.

  本发明涉及吲哚乙酸类化合物，其作为CRTH2受体的拮抗剂。本发明还涉及使用这些化合物来抑制前列腺素D2及其代谢物或某些血栓素代谢物与CRTH2受体的结合，并治疗对此类抑制有反应的疾病。
• DIAGNOSIS AND TREATMENT OF ASPIRIN-EXACERBATED RESPIRATORY DISEASE (AERD)
  申请人：BRIGHAM AND WOMEN'S HOSPITAL, INC.

  公开号：US20150253327A1

  公开（公告）日：2015-09-10

  Described herein are assays and methods relating to the diagnosis, prognosis, and treatment of aspirin-exacerbated respiratory disease (AERD) by detecting and/or measuring the level of platelet-bound leukocytes in a subject or a sample obtained from a subject.

  本文描述了一种检测和/或测量受试者或从受试者获取的样本中血小板结合白细胞水平的测定和方法，用于诊断、预后和治疗阿司匹林加重的呼吸道疾病（AERD）。